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Ca
2+ Regulation of Myocyte Contractility
An elevation in intracellular Ca 2+ (known as contractile Ca 2+ ) is a critical step in the sequence of events called excitation-contraction coupling (ECC) that couple depolarization of the plasma membrane by the propagating action potential with myocyte contraction. 2 Ca 2+ is released from sarcoplasmic reticulum Ca 2+ stores via RyRs, which are activated by Ca 2+ entering the cell through L-type voltagegated Ca 2+ channels (LTCCs) opened in response to membrane depolarization. The functional coupling between Ca 2+ entry through LTCCs and RyRs is enabled by the proximity of the sarcolemma and sarcoplasmic reticulum, which lie 10 to 15 nm apart in specialized domains called dyads (Figure) . Invaginations of the sarcolemma at ~1.8-µm intervals across the myocyte distribute these signaling domains throughout the cell volume, allowing a rapid and homogenous cell-wide Ca 2+ elevation during an action potential (AP). . 3 Unlike RyRs, InsP 3 Rs also require InsP 3 for activation, thereby making them subject to control by extracellular ligands that engage phospholipase C-activating plasma membrane receptors, including GPCRs and receptor tyrosine kinase. 3 Of the 3 mammalian InsP 3 R isoforms (InsP 3 R1, InsP 3 R2, and InsP 3 R3), InsP 3 R2 predominates in cardiac muscle. 4 Although InsP 3 Rs are much less abundant than RyRs in the heart (<1:50-1:100 of RyRs), 4 substantial evidence exists for InsP 3 Rs and InsP 3 -induced Ca 2+ signaling in atrial myocytes. 5 However, because of their even lower expression in the ventricle, the importance and contribution of InsP 3 Rs to Ca 2+ signals during ECC have been questioned. 5 Signore et al 1 report that human ventricular myocytes express functional InsP 3 R Ca 2+ release channels that are responsible for the modulation of ECC by GPCR ligands such as ATP and endothelin-1. Although a role for InsP 3 in stimulating cardiac Ca 2+ release was described >2 decades ago, 6 Signore et al 1 are the first to show that the InsP 3 /InsP 3 R signaling pathway plays an important role in regulating ECC in human ventricular myocytes. Previous work had suggested that Ca 2+ release from InsP 3 R channels located in dyadic cleft augments RyR-mediated ECC and contractility ( Figure) . 7 Using an elegant combination of studies in single ventricular myocytes and intact myocardium from humans and mice, Signore microscopy. 10 Whether the same structural domains also couple to sarcolemmal ion channels or whether such signaling occurs in caveolae-rich microdomains with LTCCs that are not involved in ECC 11 remains to be seen. Nevertheless, the functional data provided by Signore et al suggest that in addition to its role in hypertrophic gene regulation 8,9,12, GPCR/InsP 3 signaling also regulates the electrophysiological properties and excitability of cardiac muscle.
InsP 3 Signaling: Punching Above Its Weight to Control Cardiomyocyte Function
In ventricular myocardium, InsP 3 Rs are expressed at exceedingly low levels relative to RyR. The Ca 2+ current they conduct is only a quarter of that of RyRs. 13 InsP 3 is generated at a very low level in cardiac myocytes relative to other tissues, 14 thereby limiting the number of channels opened. Together with the exponential decay in Ca 2+ concentration with distance from the source channel, 15 the low density and Ca 2+ flux through InsP 3 Rs would prevent a significant elevation in intracellular Ca. 2+ How can this channel then contribute so greatly to cardiomyocyte function, in both regulating ECC and promoting hypertrophic gene transcription? A likely mechanism involves localization of the InsP 3 R proximal to its signaling effectors. Analogous to P/Q channels and BK Ca channels in smooth muscle, 16 7 This mechanism has also been proposed to explain the increased spark frequency in rabbit and rat ventricular exposed to InsP 3 17,18 and may underlie the positive inotropic action of GPCR/InsP 3 signaling in human myocytes. This cross-talk between InsP 3 Rs and RyRs is likely to make a greater contribution to the augmented GPCR/InsP 3 signaling observed in hypertrophic and failing hearts that exhibit significantly elevated InsP 3 R expression levels. 1, 18 Interestingly, Signore et al do not find evidence for InsP 3 R-RyR coupling in mouse ventricular myocytes. In mice, the positive inotropic effect of GPCR agonists and InsP 3 appears to be exclusively the consequence of AP prolongation and suggests an alternative model of coupling of InsP 3 R that controls cardiac excitation (Figure) . The functional results by Signore et al 1 suggest that in murine myocardium a pool of functional InsP 3 R exists outside the dyad that couples directly to membrane ion channels or transporters membrane. Signore et al 1 demonstrate that GPCR/InsP 3 signaling activates NCX and suggest enhanced NCX inward currents as a culprit responsible for the InsP 3 -induced AP prolongation and membrane depolarization. However, it appears unlikely that the NCX effect reported by Signore et al 1 is solely responsible because enhanced NCX, while prolonging the AP in the short term, would eventually deplete cellular Ca 2+ stores and result in reduced contractility. Thus, InsP 3 signaling likely modifies other membrane ion channels that either directly prolong the cardiac AP or cause a net increase in Ca 2+ influx into the cell. Consistent with this idea, a profound effect on membrane electrophysiology was observed in mouse ventricular myocytes exposed to Fas ligand. 19 Fas ligand caused an InsP 3 -dependent increase in AP duration, depolarized resting membrane potential, decreased I to , and increased arrhythmic events. 19 Furthermore, there is extensive cross-talk between signaling messengers downstream of GPCR other than InsP 3 that also regulates the activity of LTCCs, NCX, and the sodium-hydrogen exchanger 20 ( Figure) , which likely are also involved in the regulation of resting membrane potential and AP duration in response to InsP 3 -induced Ca 2+ release.
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